Introduction
The suggestion that inflammation may participate in Alzheimer's disease pathogenesis was first articulated about 20 years ago, and despite two decades of work, many of the central questions regarding the inflammatory response in the Alzheimer's disease (AD) brain remain unanswered (Akiyama et al., 2000) . In the course of work in this area, we have come to a more sophisticated understanding of the role of microglia, the principal immune effector cell in the nervous system, in the diseased brain. The initial work documented the presence of phenotypically activated microglia that were found to surround amyloid deposits in the brain and invest the plaques with their processes. The Alzheimer's brain was also found to have elevated levels of a number of microglial-derived cytokines and other immune mediators, reflective of a chronic inflammatory environment in the AD brain. It was postulated that this proinflammatory milieu was neurotoxic and acted to accelerate and exacerbate disease progression, and this remains the prevailing view.
An influential review by Wyss-Coray and Mucke (2002) helped catalyze a reevaluation of the roles of microglia in the diseased brain. They argued that the inflammatory response is multifaceted, with both detrimental actions that promote neurodegeneration as well as a spectrum of actions that promote neuronal survival and tissue repair. In the ensuing years, some of the details have been filled in, but investigation on the basic question of the role in microglia-mediated responses in the AD brain has only led to generation of a new array of Neurobiology of Disease 37 (2010) 503-509 
